These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25778293)

  • 21. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.
    Chaher N; Arias-Pulido H; Terki N; Qualls C; Bouzid K; Verschraegen C; Wallace AM; Royce M
    Breast Cancer Res Treat; 2012 Jan; 131(2):437-44. PubMed ID: 21360074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory breast cancer: A review from our experience.
    Mele M; Sørensen AS; Bruun J; Funder JA; Tramm T; Bodilsen A; Nielsen HM; Christiansen PM
    Breast Dis; 2019; 38(2):47-55. PubMed ID: 31256114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
    Weiss A; Menen RS; Lin HY; Shen Y; Rosso KJ; Shaitelman S; Woodward W; Valero V; Ueno NT; Bedrosian I; Babiera G
    Breast Cancer Res Treat; 2018 Jun; 169(3):615-623. PubMed ID: 29460033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival analysis of breast cancer subtypes in patients with spinal metastases.
    Wang M; Jensen AB; Morgen SS; Wu CS; Sun M; Li H; Dahl B; Bünger CE
    Spine (Phila Pa 1976); 2014 Sep; 39(19):1620-7. PubMed ID: 24979144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
    Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
    J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p16 and pRB in invasive breast cancer.
    Shin E; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer.
    Postlewait LM; Teshome M; Adesoye T; DeSnyder SM; Lim B; Kuerer HM; Bedrosian I; Sun SX; Woodward WA; Le-Petross HT; Valero V; Ueno NT; Lucci A
    Ann Surg Oncol; 2021 Dec; 28(13):8610-8621. PubMed ID: 34125346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of breast cancer subtypes and patterns of metastasis on outcome.
    Kast K; Link T; Friedrich K; Petzold A; Niedostatek A; Schoffer O; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Breast Cancer Res Treat; 2015 Apr; 150(3):621-9. PubMed ID: 25783184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancer cases.
    Hoffman HJ; Khan A; Ajmera KM; Zolfaghari L; Schenfeld JR; Levine PH
    Am J Clin Oncol; 2014 Aug; 37(4):315-21. PubMed ID: 23241503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
    Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
    Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
    Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
    Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
    PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
    Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
    Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
    Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.